In this study, utilization rates of antiviral therapy were 57% for patients with HBV-associated HCC and 35% for patients with HCV-associated HCC. Antiviral therapy initiated before or within 6 months ...
SAN FRANCISCO -- A new type of COVID-19 therapy is showing promise as a new tool to hijack the virus and slow down variants. It's a new weapon that could be added to the arsenal against COVID-19.
Just as bacteria can develop antibiotic resistance, viruses can also evade drug treatments. Developing therapies against these microbes is difficult because viruses often mutate or hide themselves ...
Among adults hospitalized with influenza-associated pneumonia, delayed vs timely antiviral treatment initiation was associated with greater 30-day mortality risk. Delayed antiviral therapy initiation ...
Please provide your email address to receive an email when new articles are posted on . Adjusted analysis demonstrated no association between nucleos(t)ide analogue retreatment and HBsAg seroclearance ...
For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to ...
Antiviral therapy holds promise in the secondary prevention of coronavirus disease 2019 (COVID-19) by preventing disease progression and thus reducing the severity of illness and the burden on ...
SAN FRANCISCO, CA—December 9, 2021—As the SARS-CoV-2 virus mutates, new variants emerge that can better evade immunity and spread more widely. This causes an ongoing race, in which scientists and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Antiviral therapy reduced incidence of long COVID-19 ...
A drug once designed for dengue virus, then quietly abandoned by industry, is suddenly back in the spotlight, and it may be ...
A new drug being developed by Pfizer offers the possibility of nearly putting an end to deaths from COVID-19. When given within five days of the onset of symptoms, the antiviral therapy, called ...